---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-015913"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:19:45.229174+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics reports FY2023 net loss of $121.8M; cash runway into 2026, pipeline milestones set for 2024

## Summary
- Cash and marketable securities $232.9M as of Dec 31, 2023, expected to fund operations into 2026.
- Net loss $121.8M ($2.02/share) for FY2023 vs $115.4M ($2.44/share) for FY2022.
- R&D expenses increased to $103.4M from $92.9M; G&A expenses decreased to $28.9M from $30.7M.
- PRT3789 (SMARCA2 degrader) on track for monotherapy dose escalation mid-2024; combo with docetaxel initiated H1 2024.
- PRT2527 (CDK9 inhibitor) to initiate combo with zanubrutinib Q1 2024; PRT7732 (oral SMARCA2 degrader) IND filing H1 2024.

## SEC filing metadata
- accession: 0000950170-24-015913
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/0000950170-24-015913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/prld-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-015913
- JSON: https://secwatch.observer/filing/0000950170-24-015913.json
- Plain text: https://secwatch.observer/filing/0000950170-24-015913.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/0000950170-24-015913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.